



***FDA Perspective on the
Development of an Adenoviral
Standard***


Stephanie L. Simek, Ph.D.
CBER/OTRR






Background/History

- ◆ 1993 Adenoviral vectors used in CF Protocols
- ◆ CF Foundation calls for vector standard
- ◆ 1999 Development of RAC AdSAT working group
- ◆ 1999 RAC Safety Symposium
- ◆ Oct. 5th Williamsburg BioProcessing Foundation meeting




Recommendations of RAC AdSAT Working Group

- ◆ Development of qualitative, quantitative vector standards - Adenovirus
 - ◆ determine particle number
 - ◆ determine infectious titer
- ◆ Allow comparison of toxicities observed in different studies
 - ◆ preclinical
 - ◆ clinical




Perspectives/Issues

- ◆ Concern over precision and accuracy of adenoviral titers
 - ◆ particle counts (multiple methods used)
 - ◆ infectious units (best 30% imprecision)
- ◆ Sharp threshold effect in dose/toxicity curve




Perspectives/Issue (cont.)

- ◆ Consistency in clinical dosing
 - ◆ dose control
 - ◆ closer approach to maximum tolerated dose
 - ◆ smaller dose increments
 - ◆ analysis of dose related adverse events
- ◆ Safety concerns
 - ◆ RCA: how much is safe?
 - ◆ toxicity of vector particle




Approaches

- ◆ Standards Development
 - ◆ physical: particle counts
 - ◆ biological: infectious particle titer
 - ◆ procedural: development of SOPs
- ◆ Precedent
 - ◆ RCR standard
 - ◆ CBER/ATCC /industry/academia collaboration




FDA Initiatives

- ◆ Collaboration with industry and academia to develop standard
 - ◆ Participation in adenoviral standardization working group
- ◆ Adenovirus research group




Collaboration with Industry/Academia

- ◆ Oct. 5, 2000 Ad vector conference
 - ◆ organized by WBF in conjunction with FDA/industry/Academia
- ◆ Consensus to develop well characterized standard
- ◆ FDA take lead using a working group approach




Leveraging

- ◆ Working with others outside CBER to meet public health responsibilities
- ◆ Investing resources in collaboration with others
- ◆ Allows for flexibility and more rapid movement
- ◆ <http://intranet.fda.gov/leveraging/>




Leveraging Agreements

- ◆ Feb 1 meeting Co-Sponsorship agreement
 - ◆ Allows for public discussion and input
- ◆ WBF-FDA Partnership Agreement
 - ◆ Allows for partnership between FDA/WBF/industry
 - ◆ Participation of FDA in development of a voluntary industry standard
 - ◆ Identify relevant criteria in production, and distribution of adenoviral standard
 - ◆ Improve ability to evaluate safety of adenoviral GT products




FDA's Role in Working Group

- ◆ Responsible for leading process to evaluate and select group(s) to manufacture, characterize, and distribute the standard
- ◆ Agreement with WBP Foundation
 - ◆ serve as “facilitating entity” for WG and FDA
 - ◆ post RFAs, announcements, meeting minutes
 - ◆ oversee the performance of each contractor





FDA's Role in Working Group (cont.)

- ◆ Review Proposals for vector production
- ◆ Make recommendation for selection of appropriate group(s) to manufacture, characterize and distribute standard.
- ◆ Set testing qualifications for standard
- ◆ collate data from standard testing
- ◆ provide guidance to WG




Adenovirus Production Scheme





Adenoviral Research Initiative

- ◆ Interaction of human and murine adenoviral vectors with viral receptors
- ◆ effect of receptor interaction on viral tropism and pathogenesis



What will be Accomplished by Standard Development

- ◆ Production of more consistent, safer, quality adenoviral vectors
- ◆ Allow comparability between preclinical studies
- ◆ Allow comparability between clinical studies
- ◆ Development of regulatory policy